MGMT Gene Silencing in High Grade Diffuse Gliomas
Author Information
Author(s): Singh Alka, Singh Anurag, Agrawal Sarita, Jaiswal Awadhesh, Jaiswal Sushila
Primary Institution: Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Hypothesis
To assess the frequency of MGMT promoter methylation in WHO grade 4 diffuse glioma patients and study their prognostic role and clinicopathological correlations.
Conclusion
Methylation of the MGMT promoter is more frequent in grade 4 diffuse gliomas that exhibit IDH1 immunopositivity and loss of ATRX expression, and it is associated with better survival outcomes in patients receiving temozolomide chemotherapy.
Supporting Evidence
- 38.2% of the studied glioma patients showed methylation of the MGMT promoter.
- Patients with methylated MGMT promoter had a median overall survival of 29.73 months compared to 10.20 months for those with unmethylated MGMT.
- Methylated MGMT promoter was significantly associated with longer survival in patients receiving temozolomide chemotherapy.
Takeaway
This study found that patients with a specific gene change in their brain tumors tend to live longer when treated with a certain type of chemotherapy.
Methodology
A two-year prospective cohort study was conducted on 89 WHO grade 4 diffuse glioma patients, assessing MGMT methylation using methylation-specific PCR.
Participant Demographics
{"mean_age":46.78,"gender_distribution":{"male":63,"female":26}}
Statistical Information
P-Value
p = 0.050
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website